fullofbeans
10-15-2007, 02:14 PM
[they] conducted a clinical study to evaluate the benefits of Taxol in patients with early breast cancer. This study included data from over 1,320 women with breast cancer that had spread to the lymph nodes under the arms (node-positive). All patients had been treated with chemotherapy consisting of Adriamycin® (doxorubicin) plus Cytoxan® (cyclophosphamide). One group of patients was then treated with Taxol, while the other group received no further chemotherapy.
Patients who were HER2-negative and ER-positive derived no benefit from the addition of Taxol.
Patients who were HER2-positive and either ER-positive or ER-negative had a 40% reduced risk of a cancer recurrence with the use of Taxol.
http://www.ufscc.ufl.edu/Patient/cancernews.aspx?section=cancernews&id=40690
Interesting..
Patients who were HER2-negative and ER-positive derived no benefit from the addition of Taxol.
Patients who were HER2-positive and either ER-positive or ER-negative had a 40% reduced risk of a cancer recurrence with the use of Taxol.
http://www.ufscc.ufl.edu/Patient/cancernews.aspx?section=cancernews&id=40690
Interesting..